Therapy News and Research

RSS

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

Medtronic, Inc. today announced that the company has received CE (Conformité Européenne) Mark approval for Medtronic Deep Brain Stimulation (DBS) Therapy in Europe as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus, which is part of a circuit involved in seizures.

17 Sep 2010

FDA approves CRT-D device to treat heart failure patients

The U.S. Food and Drug Administration today approved a new indication for three cardiac resynchronization therapy defibrillators (CRT-D) used to treat certain heart failure patients.

17 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

Abbott to present two drug eluting stents data at TCT symposium

Abbott today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25.

17 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

Intensive care diary entries can reduce PTSD rates: Study

Some intensive care patients develop post-traumatic stress syndrome (PTSD) after the trauma of a difficult hospital stay, and this is thought to be exacerbated by delusional or fragmentary memories of their time in the intensive care unit. Now researchers writing in BioMed Central's open access journal Critical Care have found that if staff and close relatives make a diary for patients, featuring information about their stay and accompanied by photographs, PTSD rates can be significantly reduced.

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.

16 Sep 2010

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

Researchers find clue behind ASD affecting males than females

New research from the Centre for Addiction and Mental Health (CAMH) and The Hospital for Sick Children (SickKids), both in Toronto, Canada provides further clues as to why Autism Spectrum Disorder (ASD) affects four times more males than females. The scientists discovered that males who carry specific alterations of DNA on the sole X-chromosome they carry are at high risk of developing ASD. The research is published in the September 15 issue of Science Translational Medicine.

16 Sep 2010

Professor advocates steps to help health care industry increase patient understanding of health information

Studies show that nearly half of all Americans have difficulty understanding health information. Confusing medical directions, such as dosage and timing of prescription medicine, can lead to serious consequences including health setbacks, inappropriate hospital admissions and, sometimes, death. Now, researchers at the University of Missouri School of Health Professions are examining what health care facilities can do to increase patient understanding and positive outcomes.

16 Sep 2010

BCBC Consortium aims to develop cell-based therapy for insulin delivery

Oregon Health & Science University's Markus Grompe, M.D., will lead a multi-center team of scientists selected to participate in the prestigious Beta Cell Biology Consortium (BCBC). Funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the consortium's long-term goal is to develop a cell-based therapy for insulin delivery in type 1 diabetes patients.

16 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

Research suggests methodical approaches to control severe aggression among children with ADHD

Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine, and colleagues, found that almost half of children with attention-deficit/hyperactivity disorder whose aggressive behaviors had not been effectively controlled during routine outpatient care could achieve near absence of aggressive, explosive behavior when implementing "first-line" stimulant treatments for ADHD tailored to individual needs, along with behavioral therapy.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

16 Sep 2010

Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000

Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute of the USA, and is now actively recruiting patients for treatment.

16 Sep 2010

Scientists reveal techniques to extend organ transplant life

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

16 Sep 2010

Therapy News and Research

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

FDA approves CRT-D device to treat heart failure patients

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

Abbott to present two drug eluting stents data at TCT symposium

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

Intensive care diary entries can reduce PTSD rates: Study

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Researchers find clue behind ASD affecting males than females

Professor advocates steps to help health care industry increase patient understanding of health information

BCBC Consortium aims to develop cell-based therapy for insulin delivery

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

Research suggests methodical approaches to control severe aggression among children with ADHD

Study finds GRK2 molecule promotes cell death after heart attack

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000

Scientists reveal techniques to extend organ transplant life

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News